Cost Effectiveness of Botulinum Toxins for the Treatment of Depression:Preliminary Observations
January 2010 | Volume 9 | Issue 1 | Original Article | 27 | Copyright © January 2010
Kenneth Beer MD PA
The standard of care for the treatment of depression involves pharmacologic therapy with selective serotonin reuptake inhibitors
(SSRIs). Cognitive therapy is typically utilized in addition to a pharmacologic intervention. However, the benefits of the drugs used
may be marginal compared with placebo yet the costs associated with their use continue to increase. One potential treatment for
depression utilizes botulinum toxins. At the present time there is a small body of evidence supporting their use for depression, the
potential efficacy and cost effectiveness of this treatment warrants further consideration including head to head clinical trials.